Trinity Biotech plc(TRIB)Earnings, Financials & Key Ratios

TRIB•NASDAQ

$0.40

Price updated Jul 7, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryPoint-of-Care and Rapid Testing

AboutTrinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.Show more

Revenue$44M-28.9%
EBITDA-$9M+54.8%
Net Income-$37M-17.6%
EPS (Diluted)-2.00-13.0%
Gross Margin38.57%+10.7%
EBITDA Margin-19.94%+36.4%
Operating Margin-26.07%+24.2%
Net Margin-85.36%-65.3%

TRIB Price & Volume

Trinity Biotech plc (TRIB) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Contraction Threatens Corporate Solvency

Investment Thesis • Updated 2025Q4

VerdictNegative: The company's precarious financial position is underscored by a TTM net loss exceeding $37M and a current ratio of 0.25

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Insolvency and liquidity risk

Key Thesis Takeaways

Trinity Biotech faces a precarious outlook characterized by a 30.2% year-over-year revenue decline in 2025Q4 and a deteriorating equity position that has reached a $72.0M deficit.
The company's aggressive transition into the competitive CGM market appears hampered by an acute liquidity crisis, evidenced by a current ratio of 0.25 and a reliance on debt that has ballooned to $138.0M.
Investors should monitor the firm's ability to stabilize its core diagnostic business, as the current trajectory suggests significant risks to long-term operational viability.

Verdict Logic

which suggests an unsustainable path toward potential insolvency.

TRIB Growth Metrics

Trinity Biotech plc (TRIB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-7.94%

5 Years-15.56%

3 Years-11.2%

TTM-28.74%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-17.73%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM26.64%

Return on Capital

10 Years-16.49%

5 Years-34.65%

3 Years-48.99%

Last Year-64.95%

TRIB Recent Earnings

Trinity Biotech plc (TRIB) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (30%)

Q3 2026Latest

Jun 16, 2026

Metric

Actual

Est

EPS

$0.23+25.8%

$0.31

Rev

—

$11M

Q2 2026

Apr 30, 2026

Metric

Actual

Est

EPS

$0.90-181.3%

$0.32

Rev

$11M-26.2%

$15M

Q4 2025

Dec 23, 2025

Metric

Actual

Est

EPS

$0.32+37.3%

$0.51

Rev

$14M+35.7%

$11M

Q2 2025

May 15, 2025

Metric

Actual

Est

EPS

$1.02-240.0%

$0.30

Rev

$16M-0.9%

$16M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest	Jun 16, 2026	$0.23vs $0.31+25.8%	—vs $11M
Q2 2026	Apr 30, 2026	$0.90vs $0.32-181.3%	$11Mvs $15M-26.2%
Q4 2025	Dec 23, 2025	$0.32vs $0.51+37.3%	$14Mvs $11M+35.7%
Q2 2025	May 15, 2025	$1.02vs $0.30-240.0%	$16Mvs $16M-0.9%

Based on last 12 quarters of dataView full earnings history →

Latest TRIB News

Recent stock market news and headlines for Trinity Biotech plc (TRIB)

GlobeNewsWire·5 days ago

New Trinity Biotech Clinical Trial Data Shows Its CGM+ Technology Tackles a Major CGM User Problem by Going Beyond Glucose-Only Monitoring

- Analysis of over 5,000 hours of clinical wear data validates Trinity Biotech's CGM+ 's purpose-built capability to distinguish nocturnal compression-related false lows from true blood glucose lows - Demonstrates practical value of Trinity Biotech's proprietary multi-sensor wearable biosensor technology beyond glucose-only CGM monitoring - Reinforces differentiation opportunity for CGM+ within the $15 billion1 global CGM market DUBLIN and WILSONVILLE, Ore., July 02, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced clinical study results demonstrating that its next-generation CGM+ wearable biosensor platform has successfully delivered a purpose-built capability to identify nocturnal compression-related false low glucose events, with its differentiated technology addressing a common limitation of conventional continuous glucose monitoring (CGM) systems.

GlobeNewsWire·Jun 30, 2026

Trinity Biotech's Trinovium Secures Open Compute Project Membership, Advancing Hyperscale Market Access and Commercial Validation for AI Data Center Liquid Cooling

- Milestone an important step in launching Trinovium within the global AI data center ecosystem - Data center liquid cooling market projected to expand from $4 billion in 2026 to $27 billion by 2033 1 DUBLIN and WILSONVILLE, Ore., June 30, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that Trinovium, its recently established subsidiary focused on high-performance liquid cooling solutions for AI data centers, has secured Silver Membership in the Open Compute Project (OCP), providing Trinovium with a platform to directly engage with one of the most influential global ecosystems shaping next-generation data center infrastructure.

GlobeNewsWire·Jun 29, 2026

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

DUBLIN, June 29, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.

GlobeNewsWire·Jun 23, 2026

Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market

- New subsidiary will leverage existing US and EU manufacturing capacity, high-purity fluid expertise, and analytical technologies to target liquid cooling performance and reliability in AI and high-performance computing environments

GlobeNewsWire·Jun 16, 2026

Trinity Biotech Awarded Significant Orders for Over 2 Million TrinScreen HIV Tests And Reports Q1 2026 Financial Results

– Orders reinforce strong demand outlook in global health markets and supports 2026 revenue and profitability targets

Peers Comparison

Key metrics vs top competitors for Trinity Biotech plc (TRIB)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
TRIBTrinity Biotech plcCurrent	$0.40	$4.14M	-0.20	-28.87%	-85.36%	—	—
OSUROraSure Technologies, Inc.	$4.32	$310.89M	-4.60	-38.1%	-61.93%	-15.09%	—
CHEKCheck-Cap Ltd.	$1.86	$10.88M	-0.43	—	—	—	—
LMATLeMaitre Vascular, Inc.	$105.70	$2.41B	41.94	13.53%	24.35%	16.19%	—
QDELQuidelOrtho Corporation	$17.00	$1.16B	-1.02	-1.89%	-45.57%	-56.31%	—
CTKBCytek Biosciences, Inc.	$4.56	$588.89M	-8.77	0.52%	-36.25%	-20.77%	—

Compare TRIB vs Peers

Trinity Biotech plc (TRIB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs OSUR

Most directly comparable listed peer for TRIB.

Scale Benchmark

vs TMO

Larger-name benchmark to compare TRIB against a more recognizable public peer.

Peer Set

Compare Top 5

vs OSUR, CHEK, LMAT, QDEL

Get notified when TRIB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

TRIB Frequently Asked Questions

Trinity Biotech plc (TRIB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Trinity Biotech plc's revenue?

Trinity Biotech plc (TRIB) reported $43.9M in revenue for fiscal year 2025. This represents a 509% increase from $7.2M in 1996.

How fast is Trinity Biotech plc growing?

Trinity Biotech plc (TRIB) saw revenue decline by 28.9% over the past year.

Is TRIB profitable?

Trinity Biotech plc (TRIB) reported a net loss of $37.4M for fiscal year 2025.

Dividend & Returns

What is Trinity Biotech plc's free cash flow?

Trinity Biotech plc (TRIB) had negative free cash flow of $6.3M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in TRIB back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Jun 16, 2026

$0.23vs $0.31+25.8%

—vs $11M

Q2 2026

Apr 30, 2026

$0.90vs $0.32-181.3%

$11Mvs $15M-26.2%

Q4 2025

Dec 23, 2025

$0.32vs $0.51+37.3%

$14Mvs $11M+35.7%

Q2 2025

May 15, 2025

$1.02vs $0.30-240.0%

$16Mvs $16M-0.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

TRIBTrinity Biotech plcCurrent

$0.40

$4.14M

-0.20

-28.87%

-85.36%

—

OSUROraSure Technologies, Inc.

$4.32

$310.89M

-4.60

-38.1%

-61.93%

-15.09%

—

CHEKCheck-Cap Ltd.

$1.86

$10.88M

-0.43

—

LMATLeMaitre Vascular, Inc.

$105.70

$2.41B

41.94

13.53%

24.35%

16.19%

—

QDELQuidelOrtho Corporation

$17.00

$1.16B

-1.02

-1.89%

-45.57%

-56.31%

—

CTKBCytek Biosciences, Inc.

$4.56

$588.89M

-8.77

0.52%

-36.25%

-20.77%

—